MAP2K7 and neoplasm: Supplemental testosterone mitigates the effects of BRAF + MEK inhibition, and blockade of the androgen receptor (AR) promotes the anti-tumor activity of BRAF + MEK inhibitors in BRAF Class 1 mutant melanoma mouse models [46].